COLORADO SPRINGS, CO. 27 May, 2015 — Cannabis biotech company, Cannabis Science, Inc. today announced a collaborative drug development deal with IGXBio. The companies plan to develop a joint protocol to demonstrate potential synergistic effects of potential HIV drugs using GenePro®, a DNA-based immunotherapeutic developed by IGXBio that recently received FDA IND approval to enter into human trials.
Cannabis Science, Inc., President & CEO, Raymond C. Dabney, said in a press statement that the collaboration is intended to help provide new insights into the role of inflammation and therapeutic vaccination of HIV in treating AIDS patients. Cannabis Science will be testing, in tandem with GenePro®, it’s CS-TATI-1 treatment, which harnesses “the anti-inflammatory effects of cannabinoids to deter disease progression in AIDS patients unable to achieve control HIV replication,” Dabney said.
Cannabis Science Senior Adviser, Scientist Dr. Roscoe M. Moore, Jr., a former Asst. US Surgeon General said that the body’s immune response to HIV causes inflammation, which is a major factor in mortality among HIV-positive people. Moore said, “If inflammation can be lowered or eliminated along with HIV viral replication it will successfully improve the health and extend the lives of HIV-positive people. By partnering CS-TATI-1 and GenePro® we believe this is possible.”
IGXBio president and CEO, James Laufenberg said, ” The GenePro® technology has been published in over 150 scientific journals. GenePro® is intended to promote an anti-HIV immune response to facilitate virus control in HIV-infected subjects. The pre-clinical development to date has been largely funded by $21 million in NIH grants. Our collaboration with Cannabis Science is designed to create new products for clinical development and commercialization in addition to utilizing GenePro® in a Phase I/IIa clinical trial.”
Cannabis Science (OTC: CBIS) is a U.S. company specializing in the development of cannabis-based medicine within novel treatment approaches to illnesses. The company says, “Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions,” and that it is researching and developing a range of proprietary drugs as a part of this initial focus, including CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1.
Kansas-based IGXBio is a privately held clinical stage biotech company developing advanced DNA immunotherapies for HIV infection. The Company says its lead product candidate, GenePro®, is “an immune-therapeutic generating non-infective viral like particles by incorporating a proprietary DNA lentiviral composition that yields high levels of gene expression and non-infectious HIV protein production, inducing robust antibody and cellular immune responses. Published data in non-human primates has demonstrated production of CD8+ memory cells similar to those produced by Elite Controllers of HIV. These are individuals who represent a small percentage of the population who control HIV progression without having therapeutic drugs on board.”